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Abstract 
The dual-specific cAMP/cGMP phosphodiesterase PDE10A is exclusively localised 
to regions of the brain and specific cell types that control crucial brain circuits and 
behaviours. The downside to this expression pattern is that PDE10A is also 
positioned to be a key player in pathology when its function is perturbed. The last 
decade of research has seen a clear role emerge for PDE10A inhibition in modifying 
behaviours in animal models of psychosis and Huntington’s disease. Unfortunately, 
this has not translated to the human diseases as expected. More recently, a series 
of families with hyperkinetic movement disorders have been identified with 
mutations altering the PDE10A protein sequence. As these mutations have been 
analysed and characterised in other model systems, we are beginning to learn 
more about PDE10A function and perhaps catch a glimpse into how PDE10A activity 
could be modified for therapeutic benefit. 
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1. Introduction 
Hyperkinetic movement disorders are a heterogeneous group of clinical 
diagnoses, defined as uncontrolled excess movement that manifests in a number of 
ways, including but not limited to tremor, dystonia, tics and chorea, which for the 
context of this PDE10A review is best exemplified by Huntington’s Disease (HD) [1, 
2]. They are as frequent as hypokinetic movement disorders, best illustrated by 
Parkinson’s Disease (PD). The basal ganglia are a group of subcortical nuclei 
primarily responsible for the selection and synchronisation of movement cues from 
cortical outputs, but which also influence motivation and cognitive behaviour [3, 
4]. The striatum is the main input region of the basal ganglia and is comprised of 
principally GABAergic medium spiny neurons (MSNs), the main neuronal cell type 
lost in HD, and cholinergic interneurons [5, 6]. MSNs can be classified into two 
distinct groups based on the destination of their axonal projections and molecular 
expression patterns, especially the G-protein coupled receptors (GPCRs) 
responsible for relaying the dopamine signal [7-9]. In particular, the MSNs of the 
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so-called ‘direct’ or ‘striatonigral’ pathway, which promote movement and express 
the dopamine D1 receptor (D1R), project to the substantia nigra and the internal 
globus pallidus. While the ‘indirect’ or ‘striatopallidal’ pathway MSNs, which 
express the dopamine D2 receptor (D2R) and inhibit movement, project to the 
pallidum [10, 11].  
The activation of these distinct pathways within the striatum rely on the tuning 
of the intracellular second messenger molecules, cyclic 3’ 5’-adenosine 
monophosphate (cAMP) and cyclic 3’ 5’-guanosine monophosphate (cGMP). cAMP is 
generated in response to extracellular cues to orchestrate numerous physiological 
processes by activation of a range of effector proteins [12]. Production of this 
cyclic nucleotide is well exemplified in the dopamine system, with binding of 
dopamine to the D1R resulting in activation of the coupled stimulatory Gαs 
protein, which in turn activates adenylyl cyclases (ACs) and triggers cAMP synthesis 
and neuronal excitability through modulation of cAMP effector protein activity. In 
contrast, ligand binding to D2Rs results in inactivation of ACs through release of 
the inhibitory Gαi protein and suppresses membrane depolarisation [13]. In light of 
these opposing forces, orchestration of the temporal/spatial synthesis and 
degradation of cAMP is crucial to illicit the appropriate receptor-specific 
physiological effect. cGMP is generated by guanylyl cyclases (GCs), which in the 
brain can be membrane-bound particulate GC or soluble GC, and are activated by 
a number of different extracellular ligands or nitric oxide respectively [14, 15]. 
Shaping of cAMP and cGMP gradients in three dimensions occurs via the action of 
cyclic nucleotide phosphodiesterases (PDEs) that degrade cAMP and/or cGMP by 
hydrolysing the 3’ cyclic phosphodiester bond to produce inactive 5’-AMP and 5’-
GMP respectively. To date there have been 11 PDE families described, yet it is 
believed over 100 mRNA products exist through alternative splicing and 
transcriptional initiation sites [16, 17]. PDE families can either specifically 
hydrolyse cAMP, cGMP or possess dual specificity to hydrolyse both substrates. The 
functions of specific PDEs are uniquely influenced by their cellular localisation, 
often directed by targeting sequences within the enzyme’s N-terminal domain 
[18]. The identification of region-specific expression of different PDEs within the 
brain highlighted that an intricate crosstalk between families exists in order to 
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strictly regulate cyclic nucleotide concentration, in a cell type specific manner 
which drives specific brain circuitry and subsequent behaviour [19-21]. 
Consequently, understanding of the various PDE isoforms, their expression within 
different brain regions and the interplay between one another is fundamental in 
the future development of therapeutics targeting PDEs in the CNS. 
Across PDE families, phosphodiesterase 10A (PDE10A) is almost exclusively 
detected in the brain, although it is also present in the testis [22, 23] and 
overexpressed in several tumours [24-26]. In the brain, it is enriched in the MSNs 
of the striatum, although reduced levels of the enzyme are also present in the 
cerebellum, hippocampus and cortex [27]. PDE10A is expressed in both D1R-
containing striatonigral and D2R-containing striatopallidal MSNs [28-31]. The high 
expression of PDE10A in the dendritic post-synaptic region helps PDE10A to 
orchestrate incoming cortical glutaminergic and midbrain dopaminergic signals, 
regulating MSN sensitivity [32-34] and critically influencing various behaviours 
generated through engagement of downstream circuitry including movement and 
motivation. Simply through its distribution and implied function, somewhat 
mimicking a D2R antagonist, PDE10A inhibition has been considered as a 
therapeutic target for schizophrenia [35], and then more elegant human biology 
and brain circuitry studies have implicated this enzyme in movement disorders 
such as HD and PD [36-38]. This review article will focus on the complicity of 
striatal PDE10A malfunction and the defective cyclic nucleotide signalling in 
genetic hyperkinetic movement disorders.  
2. Structure, localisation and regulation of PDE10A within the brain 
PDE10A is an 89 kDa dual-specific phosphodiesterase, able to hydrolyse both 
cAMP and cGMP with Km values 0.26 μM and 7.2 μM respectively [39-41], although 
with a lower Vmax for cAMP compared with cGMP [41]. On a cellular level, PDE10A 
protein is present throughout the cell soma, dendrites and axons of MSNs with 
mRNA expression largely confined to the cell body [27, 42]. Outside the striatum, 
brain regions such as the hippocampus, cerebellum, brainstem and cortex, 
exhibited exclusive nuclear localisation of PDE10A [42]. Alternative splicing gives 
rise to over 30 transcripts in the human brain of which around half are human-
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specific, characterised by unique N-terminal and C-terminal regions [16, 32, 43]. 
Humans possess two prevalent splice variants of PDE10A, PDE10A1 and the more 
abundant PDE10A2, whereas in rats PDE10A2 and PDE10A3 are more prominent 
(Kotera et al., 2004). A further primate-specific isoform, PDE10A19, has also more 
recently been described [16, 43] and other variants are expected to be found as 
some novel PDE10A transcripts have been predicted to express proteins with 
specific N-termini [16]. Conserved between the human variants are a carboxyl 
terminal catalytic region, and two regulatory GAF (cGMP-stimulated PDEs, 
Anabaena adenylyl cyclases, and the Escherichia Coli transcription factor FhlaA) 
domains (Figure 1). GAF domains provide allosteric regulation sites on PDEs [44] 
and are structurally different to cAMP binding sites of the PDE catalytic domain 
and cAMP effector proteins. For the purpose of this review, the structure and 
function of the GAF domains are highly germane. 
PDE10A is unique in regard to its GAF domains, as it is the only PDE regulated by 
cAMP rather than cGMP [23]. Low concentrations of cAMP (or a synthetic GAF 
domain agonist) stimulate degradation of both cAMP and cGMP when bound to the 
GAF-B domain of PDE10A (EC50 ∼ 0.1 μM), however the enzyme is completely 
inactivated at further elevated levels of cAMP [23]. Inhibition of cAMP degradation 
has only been found at very high levels of cGMP, with an IC50 of 14 μM [39]. This 
suggests a preference of the catalytic domain for cAMP when cAMP is bound to the 
GAF-B domain, which is in agreement with previous studies showing a higher 
affinity of PDE10A for cAMP [39, 41]. In contrast, the GAF-A domain of PDE10A 
does not contain the typical cyclic nucleotide binding consensus motif, N[KR]X(5-
14)FX(3)DE or ‘NKFDE’, associated with cyclic nucleotide binding. Interestingly, not 
all GAF domains are found to bind cyclic nucleotides, and reports have also 
implicated GAF domains in protein-protein interactions, such as the 
homodimerisation of PDE2 and PDE5 [45-48]. This infers another means of 
regulation for PDE activity, through enzyme stability or subcellular localisation. 
The differential roles of the PDE10A GAF-A and -B domains will be discussed later 
in this review, as human mutations in the two domains have a distinct clinical 
presentation. 
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As mentioned above, PDE localisation in cellular micro-domains often depends 
on targeting sequences within the N-terminal region and PDE10A is no different in 
this regard. Differential encoding of the extreme amino terminal regions account 
for distinct cellular localisation, with PDE10A1 and PDE10A19 situated in the 
cytosol whereas PDE10A2 is predominantly membrane-bound [32, 33, 40, 43]. 
PDE10A2 is post-translationally and irreversibly palmitoylated at Cys11 in its 
unique N-terminal region, facilitating its membrane association and trafficking to 
dendrites (Figures 1 and 2). Protein acyltransferases ZDHHC-7 and ZDHHC-19, zinc-
finger containing DHHC-containing proteins, we previously reported to mediate 
this palmitoylation [34]. Critically, PDE10A2 contains an exclusive cAMP-dependent 
protein kinase (PKA) phosphorylation site at Thr16, which when phosphorylated 
interferes with post-translational palmitoylation at Cys11 and prevents membrane 
translocation of the enzyme (Figure 1 and 2) [32, 34]. Therefore, the intracellular 
cAMP concentration at the time of protein synthesis tightly controls PDE10A2 
localisation, and thus the compartmentalisation of the cAMP gradient through PKA 
activation. Interestingly, overexpression of PDE10A19 has also been reported to 
interfere with membrane association of PDE10A2 through a direct interaction 
between the isoforms [43]. 
 
Figure 1. Schematic representation of human PDE10A isoforms. The three major PDE10A splice 
variants differ in their N-terminal amino acid sequence, which is responsible for the distinctive 
subcellular localisation pattern. Residues implicated in PDE10A2 trafficking to the plasma 
membrane are highlighted in bold: palmitoylated Cys11 that serves as an anchor for membrane 
insertion and phospho-residue Thr16 that can prevent palmitoylation. PDE10A functional domains, 
cyclic nucleotide binding consensus motif and mutations in PDE10A GAF domains that cause 
hyperkinetic movement disorders are indicated. Amino acid numbering refers to human PDE10A2. 
 
Fine control of localised cyclic nucleotide gradients in neurons depends on the 
unique localisation of PDE10A2. Specifically, it has been reported that PDE10A is a 
member of a signalling complex bound to synaptic membranes, including N-methyl-
D-aspartate (NMDA) receptor subunits and scaffolding proteins AKAP150 and PSD95 
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(Figure 2). Phosphorylation by PKA results in PDE10A2 dissociating from this 
complex and diffusing horizontally through the plasma membrane [49]. Therefore, 
when production of cAMP overrides the degradation capacity of PDE10A, the 
enzyme dissociates from the synaptic complex and allows triggering of downstream 
signalling cascades. 
 
Figure 2. Post-translational regulation and trafficking of PDE10A. PDE10A2 palmitoylation at 
Cys11 facilitates its trafficking and insertion into the plasma membrane of MSNs where it associates 
with synaptic proteins such as PSD95, AKAP150 and NMDA receptor subunits. High local cAMP levels 
can increase PKA activation which results in the phosphorylation of PDE10A2 at Thr16 preventing 
the action of the palmitoyl acyltransferase (zDHHC). Phosphorylated PDE10A2 accumulates in the 
cytosol in line with the other two major isoforms PDE10A1 and PDE10A19.  
3. PDE10A-related hyperkinetic movement disorders 
Alterations in cyclic nucleotide levels have been extensively associated with HD, 
which results from a trinucleotide CAG repeat expansion in the first exon of the 
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huntingtin (htt) gene and is characterised by uncontrolled choreiform movements 
related to selective vulnerability of MSNs. In early stage HD, degeneration of the 
inhibitory D2R-containing striatopallidal MSNs is observed, in contrast to the 
seemingly more resilient D1R expressing cells [50]. D1R containing MSNs 
degenerate as disease progresses, which results in hypokinetic movement 
consistent with the direct pathway becoming compromised [51]. Reduced levels of 
cAMP have been measured in both post mortem brain samples from HD patients 
and mouse models [52]. Interestingly, PDE10A mRNA and protein levels are 
downregulated in HD patients and animal models of HD prior to the onset of motor 
symptoms, with this reduction correlating to disease progression and severity [36, 
37, 53-56]. Furthermore, the rate of transcriptional initiation of PDE10A was shown 
to be reduced in the striatum of R6/1 and R6/2 HD mice, indicating the possibility 
of PDE10A transcriptional repression by the mutant htt protein [37]. Conversely, 
PDE10A inhibitors have been reported to rescue transcriptional, cellular and 
behavioural deficits in HD mouse models [57, 58]. If PDE10A levels are actively 
downregulated during the progression of HD, this raises the question as to why 
inhibition of PDE10A would be therapeutically beneficial. It has been hypothesised 
that PDE10A reduction is a compensatory mechanism to restore HD-related cyclic 
nucleotides decline, which should occur very early in the course of the disease. 
This happens via the activation of the transcription factor cAMP-response element 
binding protein (CREB), increased brain derived neurotrophic factor (BDNF) 
expression and in turn, cell survival [59-61]. Such speculation was at least partially 
quashed by the results of a Phase II clinical trial led by Pfizer in HD with the 
PDE10A inhibitor PF-02545920 (ClinicalTrials.gov, NCT02197130). Unfortunately, 
PF-02545920 was shown to have no advantage versus placebo on the primary 
endpoint of the Unified-Huntington’s-Disease-Rating-Scale Total-Motor-Score 
(UHDRS-TMS) [62]. 
In addition to HD, a series of familial mutations have recently emerged 
implicating PDE10A in child-onset non-progressive hyperkinetic movement 
disorders, with symptoms reminiscent of early-stage HD [63-67]. A total of five 
separate mutations in the PDE10A gene on chromosome 6 have been reported in 14 
individuals, with all mutations creating a single amino acid substitution in either 
the GAF-A or GAF-B domain of the protein (Table 1). Our own study [63] identified 
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two familial biallelic mutations within the GAF-A domain of PDE10A. The first 
family was consanguineous and of Pakistani descent. Affected family members 
were shown to be homozygous for a c.320A>G mutation causing a cysteine to 
replace a tyrosine at amino acid position 107 (p.Y107C). Clinical manifestations 
include axial hypotonia with dyskinesia of the face, trunk and limbs, however 
cognition was unimpaired. Notably, the degree of severity differed within the 
family, the oldest member being least affected [63]. The second mutation 
(c.346G>C; p.A116P) was identified in a Finnish family, who again presented with 
global dyskinesia and profound axial hypotonia. Cognitive impairment was greater 
compared to the p.Y107C mutation, with language and movement milestones 
significantly delayed. The youngest of the p.A116P family presented with a more 
severe movement disorder, focal epilepsy and was required to feed by a 
gastrostomy tube [63]. Interestingly, patients with these mutations in the GAF-A 
domain presented with normal MRI scans. We also made a knock-in mouse model of 
the p.Y107C mutation (p.Y97C in mice). Mice homozygous for the mutation 
displayed a range of motoric phenotypes compared to mice heterozygous for the 
mutation and wild-type. This included reduced locomotor activity in an open-field, 
reduced motor coordination on a rotarod and also a modified gait. To understand 
why the mutation had these effects, we investigated PDE10A at the transcript and 
protein level. Our detailed analyses of the mouse showed a marked reduction in 
the levels of striatal PDE10A mRNA and protein. We strongly believe that the 
mutation has an impact on transcript production and/or stability and also causes 
more rapid turnover of produced protein. A functional consequence of the 
reduction was demonstrated as phosphorylated CREB was not increased upon PF-
02545920 administration compared to wild-type animals, indicating a loss of 
PDE10A activity. We also characterised levels of the PDE10A p.Y107C protein and 
transcripts after over-expression in HEK293 cells and we again identified a 
decrease in both PDE10A protein and mRNA levels compared to wild-type PDE10A 
expression. Interestingly, in this same overexpression system the p.A116P was 
shown to be even less stable than p.Y107C which might be connected to the more 
severe clinical presentation of the p.A116P family [63]. Amazingly (but perhaps 
‘predictably’ considering the data in mice and HEK293 cells) we were also able to 
show a decrease in the levels of PDE10A by PET imaging in man, albeit a single 
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subject who was old enough to participate in such a study. Using a PDE10A-specific 
radioligand, we demonstrated a 70% reduction in striatal PDE10A signal 
independent of total striatal volume loss [63]. Such elegant translation across 
species gives us some belief that elevation of PDE10A levels and/or PDE10A 
function in these familial hyperkinetic disorder syndromes might have a beneficial 
clinical effect. The directionality of PDE10A activity we suggest here is of course 
opposite to the hypothesis around PDE10A inhibition in HD.  
De novo mutations in the cAMP-binding GAF-B domain were also identified in 
four unrelated individuals of European origin [64, 65, 67]. Two of these patients 
were heterozygous for a c.898T>C mutation (p.F300L), with the other two carrying 
a c.1000T>C (p.F334L) heterozygous mutation. Additionally, two related 
individuals of Indian decent have also been identified with a c.1001T>G (p.F334C) 
substitution [66]. Patients exhibited childhood-onset, non-progressive chorea yet 
all met cognitive and developmental milestones. Unlike the GAF-A domain 
mutations, MRI scanning of affected individuals showed bilateral striatal 
hyperintensities [64-66]. Interestingly, the younger patient (11 years) with the 
p.F334L mutation showed restricted diffusion and striatal swelling, indicative of an 
active disease state. Diurnal fluctuations of chorea were reported with the p.F334L 
mutation, with symptoms most prominent within two hours of awakening, gradual 
improvement throughout the day and complete absence at night [64]. Adult 
carriers of the p.F300L mutation conversely presented striatal atrophy and 
nigrostriatal degeneration comparable to that of HD patients, who exhibit 
significant striatal volumetric loss throughout the disease correlating to motor 
impairment [65, 68]. Moreover, these patients also showed a reduction in striatal 
and globus pallidus PDE10A levels together with substantia nigra dysfunction [67]. 
On a molecular level, these mutations are located within the deep binding pocket 
of the GAF-B domain, where cAMP is bound and activates the wild-type enzyme 
[69]. cAMP has been shown to interact with the GAF-B domain tightly and 
specifically, therefore affinity or recognition of cAMP as a modulator is likely to be 
affected in these mutations [70]. Mencacci and colleagues reported that the 
p.F300L and p.F334L mutations did not affect the basal activity of the enzyme yet 
inhibited the cAMP-stimulatory effect for cGMP hydrolysis [65]. Therefore, it is 
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reasonable to assume that the symptomatic effects of these GAF-B mutations may 
interfere with the strict cAMP-dependent regulation of cyclic nucleotide 
hydrolysis. At this moment there are no comparisons of ‘GAF-A’ versus ‘GAF-B’ 
mutations across any model systems. These studies need to be conducted to 
understand how the two classes of mutation drive disease and eventually how they 
might be treated.  
Furthermore, two sisters from an Afghan family displayed hyperkinetic and 
choreatic movements, motor restlessness and hypotonia as a consequence of 
biallelic mutations within the catalytic domain of PDE10A (c.2024T > C; 
p.Leu675Pro) [71]. This would probably affect the ability to hydrolyse cyclic 
nucleotides as this amino acid forms part of the active site [72, 73]. Similar to 
mutations in the GAF-A domain, these patients showed an early manifestation of 
the symptoms and normal MRI scans [71], inferring a common malfunction of the 
enzyme activity. Finally, a compound heterozygous mutation in PDE10A outside the 
GAF domains (c.199G>C; p.E67Q and c.1873A>T; p.I625F) has been detected in one 
individual with childhood onset of paroxysmal non-kynesigenic dyskinesia [67]. In 
this case, the patient presented a fronto-parietal cortical atrophy without striatal 
degeneration, suggesting a prominent role of PDE10A not only in the basal ganglia 
but in the whole motor circuit. 
Mutation 
PDE10A 
domain 
affected 
Inheritance/ 
Dominance 
(No. cases) 
Age at 
onset 
Clinical 
presentation PDE10A imaging 
Biochemical 
impact on 
PDE10A 
Mouse models 
c.320A>G; 
p.Tyr107Cys GAF-A 
Familial/ 
Recessive  
(6) 
~ 3 mo 
Generalized 
dyskinesia of 
face, trunk and 
limbs 
Reduced PDE10A 
levels in basal 
ganglia. Normal 
brain MRI 
Reduced 
PDE10A levels 
and activity 
Deficits in motor 
control. 
Reduced striatal 
PDE10A levels 
and function 
c.346G>C; 
p.Ala116Pro GAF-A 
Familial/ 
Recessive  
(2) 
~ 4 mo 
Generalized 
dyskinesia of 
face, trunk and 
limbs. 
Development 
delay 
Normal brain MRI Reduced PDE10A levels ND 
c.898T>C; 
p.Phe300Leu GAF-B 
De novo/ 
Dominant  
(2) 
~ 7 y 
Non-
progressive 
chorea  
Reduced striatal 
PDE10A levels. 
Bilateral 
striatocortical 
atrophy 
Normal basal 
activity Reduced 
cAMP-
stimulatory 
effect 
ND 
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c.1000T>C; 
p.Phe334Leu GAF-B 
De novo/ 
Dominant  
(2) 
~ 4 y 
Non-
progressive 
chorea  
Bilateral striatal 
hyperintensities 
Normal basal 
activity Reduced 
cAMP-
stimulatory 
effect 
ND 
c.1001T>G; 
p.Phe334Cys GAF-B 
Familial/ 
Dominant  
(2) 
~ 4 y 
Non-
progressive 
chorea  
Bilateral striatal 
hyperintensities ND ND 
c.199G>C; 
p.Glu67Gln 
c.1873A>T; 
p.Ile625Phe  
N-
terminal 
region/ 
PDEase 
Familial/ 
Recessive  
(1) 
~ 6 y Paroxysmal dyskinesia 
Fronto-parietal 
cortical atrophy ND ND 
c.2024T > C; 
p.Leu675Pro  PDEase 
Familial/ 
Recessive  
(2) 
~ 7 mo 
Chorea, 
hyperkinesia 
and motor 
restlessness. 
Development 
delay  
Normal brain MRI ND ND 
Table 1. Clinical and molecular features of pathogenic PDE10A mutations. ND, Not Done. 
4. Defective cAMP signalling as a central mechanism in hyperkinetic 
movement disorders/chorea 
As described above, mutations in PDE10A are a novel cause of hyperkinetic 
movement disorders, likely highlighting that cyclic nucleotide signalling in MSNs is 
a central mechanism underlying the pathogenesis of basal ganglia disorders. 
Intriguingly, many hyperkinetic movement disorders with a genetic origin are 
caused by the mutation of a protein involved in the regulation of cyclic nucleotides 
(Figure 3) [74]. As we have seen, PDE10A is a major degradative enzyme for cAMP 
and cGMP in the striatum [49], but also expressed within MSNs are PDE1B, PDE4B, 
PDE2A, PDE7B and PDE8B [19] which together play an important role in the 
maintenance of cyclic nucleotide levels and compartmentalisation [75].  
PDE Disease Organism Biochemical impact on PDEs Reference 
PDE1B HD R6/1, R6/2 and Q175  mice 
Decline in mRNA 
levels in the striatum [36, 58] 
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PDE2A 
(recessive mutation 
in c.1439A>G; 
p.Asp480Gly) 
Childhood‐onset 
choreo-dystonia 
Human (Spanish 
male patient) 
Severe decreased 
enzymatic activity  [76, 77] 
PDE4B HD R6/2 mice 
Increased enzymatic 
activity in the cortex 
and striatum 
[78] 
PDE4AX HD R6/1 mice 
Reduction in protein 
levels in the 
hippocampus 
[79] 
PDE4D1 HD R6/1 mice 
Reduction in protein 
levels in the 
hippocampus 
[79] 
PDE4D3 HD R6/1 mice 
Reduction in protein 
levels in the 
hippocampus 
[79] 
Table 2. Other PDEs in hyperkinetic movement disorders. 
To reinforce the convergence on these specific pathways, a patient presenting 
with childhood-onset chorea associated with dystonia (not dissimilar to the PDE10A 
families) was shown to carry a homozygous missense mutation in PDE2A [76]. The 
mutation is within the cyclic nucleotide binding pocket of the GAF-B domain 
(p.D480G) and results in a severe decrease in the dual enzymatic activity of 
PDE2A, which in the striatum has a strong preference for cGMP [80]. There is 
clearly much more functional characterisation that needs to be done with this 
mutation. It will also be important to understand how a mutation in different GAF 
domains in different PDEs leads to differences in phenotypic clinical presentation. 
At the moment, some progress has been made with the underlying mechanisms of 
mutations in the GAF domains of PDE6 that lead to retinitis pigmentosa, 
achromatopsia and autosomal dominant congenital stationary night blindness. 
Thus, mutations R104W located in the GAF-A domain and Y323N and P391L in GAF-
B cause an increase proteolytic degradation of PDE6C [81] while H262N mutant 
disrupts the inhibitory interaction of Pγ reducing its ability to promote the enzyme 
folding [82]. Moreover, these changes could be the result of an aberrant 
compartmentalisation, as the GAF-A domain of PDE6 contains a rod outer segment 
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localization signal [83].Three different mutations in PDE8B, found in German, 
Japanese and Portuguese families, produce a truncated enzyme with loss of all 
functional domains and complete ablation of cAMP hydrolysing ability [84-86]. As a 
result, these patients present with autosomal dominant striatal degeneration, a 
neurologic disorder characterized by bradykinesia, dysarthria and muscle rigidity. 
On the contrary, PDE8B knockout mice exhibit improved motor performance and a 
reduced age-induced decline in motor coordination [87], which could be due to a 
different striatal expression pattern than in humans or suggestive of an 
independent gain of function phenotype for the truncated form of PDE8B.  
An aberrant increase of cAMP related to pathogenesis can also occur from 
dysfunctional adenylyl cyclase 5 (ADCY5), the most abundant AC isoform in MSNs, 
responsible for integrating signals from multiple receptors including D1 and D2 
striatal dopamine receptors [88]. Thus, several mutations in ADCY5 have been 
identified as an important cause of a wide range of mixed hyperkinetic abnormal 
movements such as dystonia, childhood-onset chorea and myoclonus [89]. The 
most recurrent missense mutation occurs at Arg418, located in the first 
cytoplasmic domain close to the Gαi binding site [90] and causes a moderate to 
severe movement disorder, whilst a mutation in the catalytic ATP–binding pocket 
(p.A726T) is associated with a milder phenotype [91]. These mutations have no 
effect on the expression of ADCY5 but they increase its catalytic activity to 
synthesize cAMP [92]. Moreover, ADCY5-null mice with a reduction in cAMP levels 
exhibit hypokinetic motor dysfunction with abnormal coordination, bradykinesia 
and locomotor impairment accompanied by a reduction in the expression of the 
D1Rand Gsα [93]. Finally, ADCY5 haploinsufficiency by a splice site mutation that 
leads to RNA instability also causes chorea and dystonia in patients [94]. The 
similar pathological manifestations caused by both ADCY5 loss- and gain-of-
function mutations emphasise the complexity of cAMP signalling which 
orchestrates a multitude of different pathways and the necessity to fine tune its 
concentration in the striatum.  
Alterations in the activity of ADCY5 by mutations in its interacting G proteins 
have also been reported to cause hyperkinetic movement disorders. GNAO1 
encodes the most commonly expressed G α-subunit (Goα) in the central nervous 
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system which couples to GPCRs including adenosine A1 and D2 receptors [95] and 
functions as an inhibitor of ADCYs [96]. There are three mutation hotspots in 
GNAO1 associated with an early-onset chorea and dystonia phenotype (Gly203, 
Arg209 and Glu246), which are important for the stabilisation of the Gα-containing 
complexes, mainly in GTP-bound active states, and locate in the region that 
partially overlaps with the putative ADCY binding site [97]. The resultant mutant 
proteins exhibit a higher activity, inhibiting ADCY and therefore decrease cAMP 
levels [98]. Dystonia has also been reported to be caused by mutations in GNAL 
which encodes the α-subunit of Golf [99, 100]. Gαolf is strongly expressed in the 
striatum, specifically in the striosome compartment [101], where it may couple to 
adenosine A2A and D1 receptors to activate ADCY5 [102]. Pathological mutations of 
GNAL lead to unstable truncated proteins, complete deficiency of functional 
activity [100] or impaired binding to D1Rs [103]. Furthermore, some mutations in 
the G-protein β subunit encoded by GNB1 have also been associated with dystonia 
[104]. The mutations in GNB1 are primarily located in exons 6 and 7 which express 
the binding surface for interactions with Gα and several downstream effectors, 
potentially affecting the production of cAMP [105, 106]. Likewise, at the receptor 
level, a mutation resulting in GPR88 truncation has been identified in a family with 
early-onset chorea [107]. This orphan GPCR is abundantly expressed both in D1R- 
and D2R- containing MSNs [108] and acts through a Gi protein to inhibit cAMP 
accumulation [109]. Similarly, Gpr88-/- mice show hyperactivity and motor 
coordination deficits [110, 111]. The intimate relationship between hyperkinetic 
movement disorders and aberrant cyclic nucleotide signalling unveil that 
cAMP/cGMP pathways could have a more prominent role in other neurological 
diseases with coordinated movement alterations. For instance, the cAMP cascade 
is impaired in Lesch-Nyhan syndrome (LSN), a neurological disease with mental 
retardation, dystonia and chorea caused by mutations in the gene encoding the 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) [112]. LSN patients exhibit 
a marked loss of striatal dopaminergic fibres without MSNs degeneration [113]. 
Accordingly, the HPRT knockout mice also display abnormal striatal architecture 
[114] that could be related to the increased expression of PDE10A and reduction of 
other cAMP effectors such as DARPP-32 [115].  
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Figure 3. Dysregulation of cAMP signalling in MSNs is associated with hyperkinetic movement 
disorders. Mutations in genes implicated in the synthesis, degradation or distribution of cyclic 
nucleotides in the striatonigral and striatopallidal neurons (represented in blue and red respectively) 
have been identified as causes of hyperkinetic movement disorders. cAMP synthesis in the striatum is 
primarily controlled by ADCY5, which has been associated with hereditary chorea. Regulation of this 
enzyme by G proteins is also critical in coordinated movement. Thus, mutations in GNAO1 that 
expresses the inhibitory Goα, in GNAL that encodes the Golfα subunit or in the β subunit-encoding 
gene GNB1, can lead to a dystonia phenotype. Furthermore, an aberrant function of the purine 
metabolic enzyme HPRT or the GPCR GPR88 are also related to a genetic origin of chorea. The 
compartmentalisation of PDEs shapes the local gradients of cyclic nucleotides in the striatum, which 
are essential for the regulation of the motor function. Accordingly, several pathogenic substitutions in 
these cAMP degradative enzymes induce movement disorders, such as PDE2A, PDE8B and 
especially PDE10A.  
5. Concluding remarks 
A convergence of human mutations driving hyperkinetic clinical disorders on 
components of the cAMP and cGMP regulatory networks highlights the importance 
of tuning levels and maintaining the correct cellular compartmentalisation of these 
critical second messenger molecules. This article has considered the consequences 
of mutations in the regulatory GAF domains of PDE10A. The GAF-A and GAF-B 
grouped mutations present quite similarly, but the GAF-A biallelic mutations seem 
more severe including an earlier age of onset and in general a more complex set of 
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clinical issues. Interestingly however, they have no obvious structural deficits as 
shown by MRI while the GAF-B patients show abnormal bilateral hyperintense 
lesions. There have been no studies to date, in cell systems or model organisms, 
where the two classes of mutations have been compared. These types of studies 
will be essential in the future to decipher how these mutations relate to disease 
pathology and to the understanding of how they manifest in patients. 
Comprehension of the molecular mechanisms within the cAMP and cGMP signalling 
systems perturbed by PDE10A GAF mutations may also inform the direction of 
novel therapeutic strategies that may alleviate symptoms in patients affected by 
the movement disorders described above. One concept that may be germane in 
this context is the development of PDE10A activators. This could be achieved 
pharmacologically using compounds that potentially lock PDE10A in an active 
conformation akin to that when cAMP is bound to the GAF domain. Bacterial, viral 
and plant GAF domains are known to associate with a varied collection of small 
molecules that are structurally unrelated to cyclic nucleotides [116] and PDEs are 
the only family of mammalian proteins that contain such domains [117]. The 
divergence between mammalian PDE GAF domains should also allow specificity of 
action if GAF activator compounds can be discovered. Another possible route to 
PDE10A enhancement would be viral transfer of PDE genes to specific brain 
regions. This strategy is currently being used for PDE6 in the retina where a loss of 
PDE6 activity promotes retinal degeneration [118]. Delivery of PDE6 using AAV8 
stabilised retinal cGMP concentrations in canine retinas and served to protect rods 
and cones from deterioration. If optogenetic delivery of PDE10A virus could be 
achieved, the spatial and temporal control of cyclic nucleotide levels in distinct 
brain regions could be orchestrated by restricted light emission and this would 
certainly guard against side-effects associated with systemic administration of 
pharmaceuticals that concomitantly change the activity of a PDE family in all 
organs, tissues and cellular locations. 
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